[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT04906863":3,"trial-entities:NCT04906863":101,"trial-summary:NCT04906863":105},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":22,"study_type":30,"primary_purpose":31,"phases":32,"enrollment_info":33,"interventions":36,"primary_outcomes":54,"secondary_outcomes":62,"sex":63,"minimum_age":64,"maximum_age":31,"healthy_volunteers":65,"eligibility_criteria":66,"std_ages":72,"locations":75,"central_contacts":93,"overall_officials":96,"references":99,"see_also_links":100},"NCT04906863","AAAQ9793","Genetic Studies of Early-onset Dementia","RECRUITING","2028-04-30","2026-04","2026-04-29","2016-09-14","Columbia University","OTHER",false,"The aim of this study is to identify genetic factors that contribute to risk and progression of early-onset dementia (loss of memory function before the age of 70 years) across all ethnic groups, including Alzheimer's Disease, mild cognitive impairment and other dementias.","The study population includes individuals with Alzheimer's disease, mild cognitive impairment, other forms of dementia, as well as cognitively healthy individuals with a family history of dementia. Participants include males and females across all racial and ethnic groups.",[18,19,20,21],"Dementia, Early Onset","Alzheimer Dementia (AD)","Mild Cognitive Impairment (MCI)","Memory Loss",[23,24,25,26,27,28,29],"Alzheimer's Disease","Memory loss","Early-onset Alzheimer's disease","Mild cognitive impairment","Normal cognition","Dementia","Genetics","OBSERVATIONAL",null,[],{"count":34,"type":35},1000,"ESTIMATED",[37,46,50],{"type":38,"name":39,"description":40,"armGroupLabels":41},"GENETIC","Blood draw","Blood draw for identification of genetic variants associated with the development of memory problems",[42,43,44,45],"Cognitively Healthy","Dementia\u002FAlzheimer's Disease","Early-onset dementia prior to the age of 65.","Mild Cognitive Impairment",{"type":13,"name":47,"description":48,"armGroupLabels":49},"Neurocognitive testing","Brief memory test",[42,43,44,45],{"type":13,"name":51,"description":52,"armGroupLabels":53},"Medical questionnaire","Collection of medical history",[42,43,44,45],[55,59],{"measure":56,"description":57,"timeFrame":58},"Genetic risk variants associated with early-onset dementia","Genetic factors will be measured through genome-wide genotyping arrays and\u002For whole-genome sequencing, and then correlated with Alzheimer disease and related phenotypes, such as cognitive impairment, functional impairment, and relevant biomarkers.","2 years",{"measure":60,"description":61,"timeFrame":58},"Changes in blood biomarkers in early-onset dementia","Blood biomarkers including plasma amyloid beta and tau protein will be assessed in blood and correlated with onset and progression of memory loss and functional impairment",[],"ALL","35 Years",true,{"inclusion":67,"exclusion":70,"raw_text":71},[68,69],"35 years and older","Individuals experiencing memory concerns or diagnosed with dementia and their family members that are unrelated healthy controls without dementia.",[],"Inclusion criteria:\n\n* 35 years and older\n* Individuals experiencing memory concerns or diagnosed with dementia and their family members that are unrelated healthy controls without dementia.\n\nExclusion Criteria:\n\n\\- Individuals with competing diagnosis such as Huntington's disease, traumatic brain injury, drug or alcohol abuse, or schizophrenia, etc., unless family members of a dementia affected individual",[73,74],"ADULT","OLDER_ADULT",[76],{"facility":77,"status":7,"city":78,"state":78,"zip":79,"country":80,"contacts":81,"geoPoint":90},"Columbia University Irving Medical Center","New York","10032","United States",[82,87],{"name":83,"role":84,"phone":85,"email":86},"Pamela del Rosario, MD","CONTACT","212-304-7284","pd2727@cumc.columbia.edu",{"name":88,"role":89},"Christiane Reitz, MD PhD","PRINCIPAL_INVESTIGATOR",{"lat":91,"lon":92},40.71427,-74.00597,[94],{"name":95,"role":84,"phone":85,"email":86},"Pamela Del Rosario",[97],{"name":98,"affiliation":12,"role":89},"Christiane Reitz, MD, PhD",[],[],{"nct_id":4,"conditions":102,"biomarkers":104},[23,28,103],"Mild cognitive disorder",[],{"nct_id":4,"found":65,"summary":106,"prompt_version":115},{"design":107,"status":108,"heading":6,"summary":109,"follow_up":110,"word_count":111,"commitments":112,"compensation":113,"drugs_mentioned":114},"This is an observational study aiming to enroll 1000 participants. It is not a treatment study, but rather looks at genetic factors.","completed","This study is looking for people aged 35 and older who are experiencing memory concerns or have been diagnosed with dementia, as well as healthy family members without dementia. The goal is to understand the genetic factors that contribute to early-onset dementia (memory loss before age 70), including Alzheimer's Disease and mild cognitive impairment (MCI). Participants will have a blood draw to look for genetic changes, take a brief memory test (neurocognitive testing), and complete a medical questionnaire. The researchers hope to identify genetic risk factors and changes in blood markers related to early-onset dementia within two years. The study is currently recruiting participants.","The study will measure genetic risk variants and changes in blood biomarkers over two years.",104,"You would have a blood draw, a brief memory test, and complete a medical questionnaire.","Not stated in the trial record.",[39,47,51],"v2"]